drugset / Trial / NCT00131911
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase II trial is studying how well sorafenib tosylate works in treating patients with progressive metastatic neuroendocrine tumors. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Timeline
- Start
- 2005-06
- Primary completion
- 2010-10
- Completion
- 2013-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 400 mg | Oral |